In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Research laboratory suppliers consider clinical targets in M&A (Mergers and Acquisitions) activities

This article was originally published in Clinica

Executive Summary

The drive to extend product lines and exploit life science technologies were key reasons for the high level of M&A activity among medical device and diagnostics companies in the second half of the 1990s. Manufacturers' pursuit of diversification, and other industry twists and turns, are discussed in the 2000 edition of Mergers and Acquisitions in the Laboratory Equipment and Analytical Instrument Industries, from PJB Publications' Infocom reports, reviewed here by author Dr Gordon Wilkinson.

You may also be interested in...



Brazil Levels Medtech ICT Tariffs Playing Field

All medtech in Brazil will soon be subject to standardized industrial tariffs and development-related fiscal incentives, following a reform of rules relating to ICT across all industries.

Moderna Marches First Coronavirus Vaccine To US Test

The first vaccine for the new coronavirus has entered the clinic, with US firm Moderna leading the race.

SK Bio Begins New Coronavirus Vaccine Development Using Versatile Platform

Korean vaccine specialist SK Bioscience moves to develop versatile platform technology to deal with outbreaks of infectious diseases such as the new coronavirus, as the number of infections in the country surges.

Topics

UsernamePublicRestriction

Register

MT076814

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel